Biogen has estimated that around 1.5 million Americans would be eligible for treatment with aducanumab, which is given by monthly infusion, raising concerns about costs to the healthcare system.
Source: Jerusalem Post
Full Article: FDA approves Biogen Alzheimer's drug for use
